Myelodysplastic Syndromes, Version 2.2015

[akemwave]

Dated April 2015, this paper incorporates much new information. Watch and wait must now include Reevaluate. It may be time to revisit the lab test routine. Myelodysplastic Syndromes, Version 2.2015

http://www.jnccn.org/content/13/3/261.long

Abstract: The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.